Top Picks for Large-Cap Biotechnology
Posted in Healthcare Stocks on October 19th, 2009As part of our Exclusive Biotechnology Report we spoke with Maged Shenouda, Executive Director, Health Care Group of UBS Investment Research gave us some great insight into Large Cap Biotechnology and his top picks;
Mr. Shenouda: So right now, we like Gilead(GILD). They have a dominant HIV franchise. Their base business is doing well. We also expect upside from clinical data releases next year with a product called GS 9350, their non-protease booster, as well as elvitegravir, their integrase inhibitor. Combine that with potential changes for HIV treatment guidelines, where patients would be treated earlier at CD4 counts of 500 and less versus 350 currently. This would bring more patients into treatment. So that’s more of a shorter-term commercial upside opportunity.
Then we like Celgene (CELG). We think it’s the best growth story in biotech. Its geographic expansion outside of the U.S. is going to maintain its top-line growth at the top of its peer group. We also expect positive data releases. Specifically, we anticipate positive detailed data from the MM- 015 trial at the ASH meeting in December. We also like Human Genome Sciences (HGSI). We’re excited about the prospects of BENLYSTA, that’s its lead development-stage product for the treatment of lupus or SLE. They had a positive readout with the first Benlysta Phase III trial. We think that they are likely to have a positive readout with the second Phase III trial, called BLISS- 76, reading out in November. We also believe this is a strong acquisition target.
Follow us on TWITTER
the others. So far, its results have been nothing to brag about. In a story hat appeared on 


